3
Views
0
CrossRef citations to date
0
Altmetric
Review

Recent advances in the treatment of advanced or recurrent endometrial cancer

&
Pages 521-532 | Published online: 10 Jan 2014
 

Abstract

Advanced or recurrent endometrial cancer is relatively uncommon and carries a poor prognosis. Recent decades have failed to witness a significant improvement in treatment outcomes for women with advanced disease, and mortality rates remain high. The precise role of surgical debulking, radiotherapy, hormonal therapy and cytotoxic chemotherapy in the treatment of advanced or recurrent disease is unclear. An improved understanding of the molecular pathology of endometrial cancer has allowed biologically relevant targets to be characterized and novel drugs are now being tested in early-Phase clinical trials. This review will present the evidence for the therapeutic options currently available to women with advanced or recurrent endometrial cancer and describe the progress that is being made in the field.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Log in via your institution

Log in to Taylor & Francis Online

There are no offers available at the current time.

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.